Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.90), $0.26 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $4.73 million versus the consensus estimate of $15.97 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.